Since the approval of exenatide, the initial commercial GLP-1 receptor agonist (GLP-1 RA), by the US Food and Drug Administration in April 2005 for treating T2DM, GLP-1 RAs have become a crucial option for the treatment of T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.